John Bradley Sorenson Sells 6,000 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) SVP John Bradley Sorenson sold 6,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $42.79, for a total transaction of $256,740.00. Following the transaction, the senior vice president now directly owns 42,385 shares of the company’s stock, valued at $1,813,654.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

John Bradley Sorenson also recently made the following trade(s):

  • On Monday, July 15th, John Bradley Sorenson sold 3,728 shares of Boston Scientific stock. The shares were sold at an average price of $42.30, for a total transaction of $157,694.40.

Shares of NYSE:BSX traded down $1.14 during trading on Wednesday, reaching $41.72. The company had a trading volume of 3,396,326 shares, compared to its average volume of 7,357,786. The business’s fifty day moving average is $42.52. The firm has a market cap of $59.17 billion, a price-to-earnings ratio of 28.38, a PEG ratio of 2.59 and a beta of 0.80. Boston Scientific Co. has a twelve month low of $31.56 and a twelve month high of $43.66. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 1.04.



Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. The company had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.64 billion. Boston Scientific had a net margin of 13.85% and a return on equity of 23.29%. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.41 EPS. On average, research analysts forecast that Boston Scientific Co. will post 1.56 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Whittier Trust Co. raised its holdings in shares of Boston Scientific by 31.5% in the 2nd quarter. Whittier Trust Co. now owns 1,069 shares of the medical equipment provider’s stock worth $46,000 after purchasing an additional 256 shares in the last quarter. Winslow Evans & Crocker Inc. raised its holdings in shares of Boston Scientific by 28.4% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 1,220 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 270 shares in the last quarter. Panagora Asset Management Inc. raised its holdings in shares of Boston Scientific by 0.5% in the 2nd quarter. Panagora Asset Management Inc. now owns 57,341 shares of the medical equipment provider’s stock worth $2,464,000 after purchasing an additional 280 shares in the last quarter. Hanseatic Management Services Inc. raised its holdings in shares of Boston Scientific by 1.4% in the 2nd quarter. Hanseatic Management Services Inc. now owns 20,714 shares of the medical equipment provider’s stock worth $890,000 after purchasing an additional 288 shares in the last quarter. Finally, BB&T Corp raised its holdings in shares of Boston Scientific by 0.5% in the 2nd quarter. BB&T Corp now owns 52,968 shares of the medical equipment provider’s stock worth $2,277,000 after purchasing an additional 288 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

BSX has been the subject of a number of analyst reports. Stifel Nicolaus boosted their target price on shares of Boston Scientific from $44.00 to $46.00 and gave the company an “in-line” rating in a research note on Thursday, June 27th. Needham & Company LLC set a $46.00 target price on shares of Boston Scientific and gave the company a “buy” rating in a research note on Wednesday, July 24th. BTIG Research set a $46.00 target price on shares of Boston Scientific and gave the company a “buy” rating in a research note on Wednesday, July 24th. Wells Fargo & Co boosted their target price on shares of Boston Scientific from $42.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, June 18th. Finally, Jefferies Financial Group boosted their target price on shares of Boston Scientific from $44.00 to $48.00 and gave the company a “positive” rating in a research note on Thursday, June 27th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $44.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: How do analysts define an oversold condition?

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.